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Abstract
Background Sleeve gastrectomy (SG) was pioneered as a two-
stage intervention for super and super-super obesity to minimize
morbidity and mortality; it is employed increasingly as a
primary procedure. Early outcomes and integrity of laparoscopic
SG (LSG) against leak using a technique incorporating gastric
transection-line reinforcement were studied.
Methods Between 2003 and 2009, 121 patients underwent
LSG (16, two-stage; 105, primary). Of the patients, 66% were
women, mean age 38.8±10.9 (15.0–64.0), and body mass
index (BMI, kg/m2) 48.7±9.3 (33.7–74.8). Bovine pericardi-
um (Peri-Strips Dry [PSD]) was used to reinforce the staple
line. Parametric and nonparametric tests were used, as
appropriate. The paired t test was used to assess change from
baseline; bivariate analyses and logistic regression were used
to identify preoperative patient characteristics predictive of
suboptimal weight loss.
Results Mean operative time was 105 min (95–180), and
mean hospitalization was 5.6 days (1–14). There was no
mortality. There were 6 (5.0%) complications: 1 intraoperative
leak, 1 stricture, 1 trocar-site bleed, 1 renal failure, and 2
wound infections. There were no postoperative staple-line
leaks. Following 15 concomitant hiatal hernia operations, 3
(20%) recurred: 1 revised to RYGB and 2 in standby. Two
post-LSG hiatal hernias of the two-stage series required
revisions because of symptoms. BMI decreased 24.7% at
6 months (n=55) to 37.5±9.3 (22.2–58.1); %EWL was 48.1
±19.3 (15.5–98.9). Twelve-month BMI (n=41) was 38.4±
10.5 (19.3–62.3); %EWL was 51.7±25.0 (8.9–123.3). Forty-
eight-month BMI (n=13) was 35.6±6.8 (24.9–47.5); %EWL
was 61.1±12.2 (43.9–82.1) (p<0.001). Preoperative BMI
was predictive of >70% of patients who experienced <50%
EWL at 6 months. At 2 weeks, 100% of type 2 diabetes
patients (n=23) were off medication (mean HbA1C, 5.9±
0.5%; glycemia, 90.0±19.9 mg/dL (p<0.01) at 3 months).
Conclusions Laparoscopic PSD-reinforced LSG as a staged
or definitive procedure is safe and effective in the short
term and provides rapid type 2 diabetes mellitus reduction
with a very low rate of complications.
Keywords Bariatric surgery . Laparoscopic . Sleeve
gastrectomy .Morbid obesity . Staple-line reinforcement .
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Introduction
Sleeve gastrectomy (SG) was approved as a primary
bariatric procedure in 2009 by the American Society for
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Metabolic and Bariatric Surgery. The operation, performed
open or laparoscopically (LSG), constitutes the gastric
portion of the biliopancreatic diversion with duodenal
switch (BPD/DS) [1]. SG was pioneered during the past
decade as the first operation of a two-stage intervention for
super and super-super obesity (body mass index [BMI,
kg/m2] >50 and >60 [2]) and/or high operative risk as a
strategy to minimize morbidity and mortality [3–7]. SG has
been employed increasingly, since 2006, as a stand-alone,
primary procedure [8–12], sometimes requiring “comple-
tion” with a second operation due to inadequate weight loss
[13, 14].
A systematic review of the literature by Brethauer et al.
reported short- and intermediate-term outcomes in 2,570
SG patients with mean overall excess weight loss (EWL) of
55.4% (range 33.0–85.0; summarized in 1,662 patients,);
46.9% (33.0–61.4; n=821) for SG performed within a
staged approach; and 60.4% (36.0–85.0; n=1, 749) when
intended as a definitive procedure [15]. In the same review,
the majority of patients with comorbid illness (n=754)
experienced comorbidity improvement or resolution; >70%
of patients experienced improved or resolved type 2
diabetes mellitus (T2DM). The efficacy of SG appears to
extend to morbidly obese patients (BMI≥40, or ≥35 with
two or more comorbidities [2]) with average operative risk
[16, 17] and to certain lower-BMI populations with severe
adiposity and/or high risk [18]. SG effectiveness as a
primary procedure is comparable to other approved bari-
atric procedures through the intermediate term [19–22],
although long-term follow-up data with which to evaluate it
are still needed [1, 23].
Use of SG is on the rise; in a recent survey of metabolic/
bariatric surgery worldwide, no SGs/LSGs were reported
performed in 2003, whereas they represented 5.4% (0.3%
SG, 5.1% LSG) of bariatric procedures reported in 2008
[24]. LSG has been described as one of the most rapid and
least difficult of bariatric procedures to perform [25]. The
complication rate for SG is reasonably low, mean 9.4%
(0–23.8) in high-risk or staged patients, and 6.2% (0–21.7)
in primary procedures; leak is the most frequently reported
complication, 2.2%, followed by bleeding, 1.2%, and
stricture, 0.6%, with low mortality, 0.19% [15]. Leak may
be related to too small a calibration of the sleeve segment,
or to imperfect closure of the gastric transection line.
Although the overall leak rate is not high, due to the
extensive resection that characterizes SG, in the context of a
proximal stricture, a persistent leak may result in total
gastrectomy as the sole surgical option [1]. At our
institution, we applied our experience in a prior randomized
trial of staple-line reinforcement in Roux-en-Y gastric
bypass (RYGB) for bleeding reduction [26] toward the
goal of minimizing leak in SG. In a consecutive series of
morbidly obese patients, we performed LSG between 2003
and 2006 as part of a planned, two-stage approach for
super-obese patients, and from 2007 to 2009, as a primary
procedure, independent of BMI, to be revised and com-
pleted if necessary. Early efficacy outcomes and the
integrity of LSG against leak using a technique incorporat-
ing gastric transection-line reinforcement were studied.
Methods
Institutional Review and Study Design
The study was reviewed and approved by the institutional
review board of San Giovanni Bosco Hospital, Naples,
Italy. Adherence to the ethical conduct standards of the
Declaration of Helsinki ensured patients' welfare [27]. The
study was retrospective, using prospectively collected data.
Patient Eligibility, Informed Consent, and Preparation
Patients seen at the hospital for treatment of their morbid
obesity underwent a multidisciplinary evaluation to consid-
er the option of bariatric surgery [28]. Eligible patients met
the International Federation for the Surgery of Obesity
(IFSO), the European Association for the Study of Obesity
(EASO), and the National Institutes of Health (NIH)
indications for bariatric procedure eligibility [29, 30].
Patients in the super obese and super-super obese categories
who qualified for LSG as a primary procedure were
informed that they were at greater risk of requiring a
second procedure if adequate weight loss was not attained
through LSG alone. Informed consent was obtained from
all patients. Each patient underwent comprehensive medical
evaluation. Prior to surgery, antibiotic prophylaxis and
venous stasis prophylaxis were instituted.
Surgical Technique
Venous stasis prophylaxis was performed by external
pneumatic compression (SCD™ Compression Sleeves;
Covidien, Mansfield, MA) at time of surgery, with
administration of low molecular heparin for a period of
20 days postoperatively and early patient mobilization the
day after surgery. Under general anesthesia, the patient was
placed in reverse Trendelenburg lithotomic position, arms
and legs abducted, with the surgeon positioned between the
patient's legs, the first assistant on the patient's left, and the
camera operator, on the right. Closed CO2 pneumoperito-
neum was induced by subcostal Veress needle insertion in
the left upper quadrant. Five trocars (T) were positioned:
(T1) a 10-mm trocar approximately 20 cm below the
xyphoid process in the midline for a 30° camera system,
(T2) a 10-mm trocar in the subcostal region on the left
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anterior axillary line, (T3) a 5-mm trocar 2 cm below the
xyphoid process for liver retraction, (T4) a 5-mm trocar on
the left mid-clavicular line and transverse umbilical line,
and (T5) a 10–12-mm trocar (for Ethicon Endo-Surgery
[EES] staplers) or a 10–15-mm trocar (for Covidien
staplers) on the right mid-clavicular line and transverse
umbilical line.
The gastrocolic ligament attached to the stomach was
opened, beginning 10–12 cm from the pylorus toward the
lower pole of the spleen. The gastric greater curvature was
freed up to the cardioesophageal junction close to the
stomach with the use of a vessel-sealing device (Ultracision
Harmonic Scalpel®, EES, Cincinnati, OH; LigaSure®,
Covidien, Mansfield, MA) sparing the gastroepiploic
vessels. Meticulous dissection was performed at the angle
of His with full mobilization of the gastric fundus. Large fat
pads of Belsey were resected to provide a clean field for
stomach resection. The esophageal hiatus was carefully
inspected for a hiatal hernia (HH). In the instance of a
hernia, the esophagus was encircled, and the diaphragmatic
crura were completely dissected to the mediastinal space.
The gastric herniation was reduced into the abdomen.
Reconstruction was performed using nonabsorbable
(0 Ethibond) interrupted sutures reinforced with a 1″×1″
pledget of bovine pericardium with collagen matrix (Peri-
Strips Dry® [PSD] with Veritas® Collagen Matrix Staple
Line Reinforcement, Synovis Surgical Innovations, St.
Paul, MN), calibrated on a 40 French orogastric bougie.
Mobilization of the stomach continued with inferior
dissection of the greater curvature toward the antrum up
to 3–5 cm from the pylorus. Serosal attachments of the
posterior gastric wall to the pancreatic capsule were divided
until visualization of the caudate lobe of the liver was
obtained. The final surgical preparation was a mobilized
stomach tethered at the celiac axis.
The anesthesiologist inserted a 40 French orogastric
calibrating bougie directed toward the pylorus along the
gastric lesser curvature. The stomach was resected with the
linear stapler parallel to the orogastric tube along the lesser
curve, starting 3–5 cm from the pylorus. The antrum was
partially resected by firing 3–5 green endoscopic linear
stapler cartridges (ETS Flex® 4.1, EES; Echelon 60®, EES;
Endo GIA 60® 4.8, Covidien) from the right-sided trocar
(T5). As the muscular layer of the stomach is thicker, the
staple line at the level of the antrum is reinforced with
seroserosal running sutures rather than staples. After
passing by the level of the angular incisure, the gastric
corpus and fundus were transected with 4–5 cartridges of
the 45-mm linear stapler or 3–4 cartridges of the 60-mm
stapler, depending on their availability in the operating
room (Endo GIA Universal®, Autosuture, Norwalk, CT;
Endopath ETS®, EES; Echelon 60®, EES), and using
multiple blue cartridges loaded with PSD to reinforce the
staple line and facilitate tissue remodeling. The buttressed
transection line was reinforced with titanium clips to obtain
perfect hemostasis; the nonbuttressed transection line was
reinforced with a manual, running, absorbable, polydiox-
anone seroserosal suture.
The calibrating bougie was replaced by a nasogastric
tube positioned in the distal stomach to perform the
methylene blue dye test for determination of staple-line
integrity. A clean sponge was placed along the transection
line, the bowel clamp was placed distal to the suture line,
and the reduced stomach was inflated with 60–80 cc of
methylene fluid; the swab and the transection line were
inspected for the presence of methylene blue dye. Follow-
ing a negative test, the resected stomach was removed
through the T5 trocar in a specimen bag, usually without
elongating the incision, and a left subcostal drain was
placed. The 10-mm trocar access sites were closed with a
suture passer (Endoclose®, Covidien, Norwalk, CT) with
2–0 absorbable vicryl suture. The 5-mm trocars were only
inspected for bleeding.
Outcomes and Data Collection
Data collection was facilitated using Microsoft Excel®
2008 (version 12.2.5, Redmond, WA). Operative time and
duration of hospital stay were recorded. Effectiveness end
points included mean BMI change from baseline at
6 months; mean %EWL at 6 months and trends in BMI
and %EWL (noted to 48 months); %EWL is calculated as
the difference in baseline and postsurgery weight divided
by the difference in baseline and ideal body weight (i.e.,
upper limit value of the medium-frame range on the
Metropolitan Life Insurance Tables [31]) multiplied by
100; and metabolic outcomes in diabetic patients at 2 weeks
and 3 months. Safety end points were perioperative and
long-term complications. Data were scheduled to be
collected preoperatively, on the day of surgery, and at
postoperative visits at 2 weeks, every 3 months for the first
postoperative year, at 1 year, and at a minimum, yearly
thereafter.
Statistical Analysis
The SPSS® software package (version 17, SPSS [IBM],
Chicago, IL) was used to perform all statistical analyses.
Continuous demographic variables were reported as mean,
standard deviation (SD), and range; categorical variables
were reported as number and percentage. Concomitant
surgical procedures and complications were also reported as
number and percentage. Continuous outcome variables
were generally reported as mean, SD, range, mean change,
and percentage change. Ninety-five percent confidence
intervals (CIs) were calculated for weight-loss outcome
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data. Fisher's exact test was used to investigate relationships
between categorical variables. Between-group comparisons
along continuous measures were carried out by means of
parametric and nonparametric tests, as appropriate (i.e.,
independent samples t test or analysis of variance
[ANOVA]; Mann–Whitney U test or Kruskal–Wallis test).
Measures of change from baseline were analyzed using
either the paired samples t test or the Wilcoxon signed-rank
test. In addition, bivariate unadjusted analyses were
performed to identify preoperative characteristics associated
with suboptimal weight loss; logistic regression was applied
in the development of the predictive model. Statistical
significance was set at p<0.05.
Results
One hundred twenty-one patients qualified to receive LSG.
Sixteen patients (from January 2003 to December 2006)
underwent LSG as part of a staged bariatric procedure.
From 2007 to 2009, 105 patients were operated on with the
intent of performing LSG as a primary procedure. One
patient who had undergone laparotomic intragastric balloon
(IB) positioning with antral rupture, bleeding, and perfora-
tion in 2005 was explored laparoscopically with the intent
of performing LSG in 2009; however, due to the poor
quality of the tissue noted during gastric preparation, the
operation performed was RYGB with gastrectomy of the
remnant stomach. A second patient, intended for staged
LSG 8 months after gastric band removal, presented with
scar tissue and a difficult gastric preparation resulting in
multiple positive intraoperative methylene blue tests at the
level of the incisura angularis corresponding to the first
buttressed transection line. After several failed attempts at
staple-line repair with gastrogastric seroserosal sutures, this
patient was converted to RYGB with distal gastrectomy.
Patient Characteristics
Baseline characteristics of intent-to-treat patients are shown in
Table 1. Sixty-six percent of patients were women. The mean
age was 38.8±10.9 (15.0–64.0). Mean absolute weight was
134.6±29.0 kg (80.0–200.0), mean BMI 48.7±9.3 (33.7–
74.8), and mean excess body weight 74.1±26.8 kg (26.3–
130.5). In operative risk assessment, American Society of
Anesthesiologists (ASA) physical status score [32] was mean
3.6±0.6 (2.0–4.0). Hypertension was the most prominent
comorbid illness (43, 36.1%), followed by obstructive sleep
apnea (OSA; 30, 25.2%), T2DM (23, 19.3%), and hyperlip-
idemia (17, 14.3%).
Prior to LSG, as a first-step in weight reduction, 32 patients
(mean weight, 167.37±31.94 kg; mean BMI, 60.91±
11.83 kg/m2; mean EW, 125.69%±49.17) were submitted
to IB positioning. After removal of the IB at 6 months, mean
weight was 146.66±29.12 kg; mean BMI was 53.28±
10.03 kg/m2. The LSG procedure was performed after IB
removal at 49±75 weeks. Only 18/32 IB patients were
admitted to surgery within 16 weeks after BIB removal, as
most of their weight loss was regained before the time of
LSG surgery.
Operative Time, Concomitant Procedures, and Hospital
Stay
Mean operative time was 105 min (95–180). Among 32
concomitant procedures, 8 (25%) were cholecystectomies,
1 (3.1%) omentectomy, 1 (3.1%) biliointestinal bypass
restoration, 7 (22%) umbilical hernia repairs, and 15 (47%)
HH reductions with cruroplasty (Table 2). One patient
underwent both the omentectomy and biliointestinal bypass
restoration. The biliointestinal bypass restoration consisted
of closure of the biliointestinal anastomosis with a linear
stapler (60-mm ENDO GIA), cholecystectomy, closure of
ileo-ileal anastomosis (T-L), and a restoration of intestinal
continuity with a new ileo-ileal anastomosis, followed by
Table 1 Preoperative patient characteristics
Characteristic Value, mean±SD (range), N=121
Age (years) 38.8±10.9 (15.0–64.0)
Height (m) 1.7±0.1 (1.5–2.0)
Absolute weight (kg) 134.6±29.0 (80.0–200.0)
Excess body weight (kg) 74.1±26.8 (26.3–130.5)
Ideal body weight (kg) 60.6±5.4 (50.5–77.6)
BMI (kg/m2) 48.7±9.3 (33.7–74.8)
ASA score 3.6±0.6 (2.0–4.0)










Celiac disease 1 (0.8)
GERD 1 (0.8)
BMI body mass index, ASA American Society of Anesthesiologists
(physical status classification score), OSA obstructive sleep apnea,
T2DM type 2 diabetes mellitus, GERD gastrointestinal esophageal
reflux disease
Percentage ideal body weight and excess body weight determined by
the Metropolitan Weight Tables for Life Insurance, 1983
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sleeve gastrectomy. The omentectomy in this patient
resulted in the complete excision of the omentum close to
its emergence from the transverse colon. Mean postopera-
tive time in hospital was 5.6 days (1–14).
Mortality, Leak Rate, and Complications
There was no perioperative or postoperative mortality in the
series. In one case of intraoperative leak (0.8%) at the level
of the incisura angularis corresponding to the first but-
tressed transection line, suture repair was not successful;
after repeating the methylene dye test with two positive
results, the procedure was converted to an RYGB. There
were no postoperative leaks in the series. Overall compli-
cations (6, 5.0%) included one stricture, treated with
endoscopic dilation; one extraluminal bleed at the trocar
site, treated with a blood transfusion; one acute renal failure
1 week after surgery, treated in the intensive care unit
(patient discharged after 10 days); and two wound
infections, managed with drainage and antibiotics (Table 2).
The patient who developed stricture postoperatively had
a gastric band removed 8 months prior to the planned LSG;
the stricture developed before the gastric angle at the level
of the last unbuttressed staple line. The patient with
postoperative bleeding experienced a decrease of hemoglo-
bin concentration from 14.5 to 11.0 mg/dL within the first
24 postoperative hours; there was no blood drainage
through the drainage tube positioned close to the excision
line. A CT contrast study in POD1 showed a large
properitoneal blood collection near the left side trocar site.
This acute bleeding was treated with blood cell unit
transfusion and resolved within 48 h.
Of the 15 patients operated concomitantly for HH, three
(20%) recurred; one of these, who had also previously
received crural repair by interrupted nonabsorbable sutures
that was reinforced with a pledget of bovine pericardium
with collagen matrix (PSD), was revised to an RYGB. Two
patients of the two-stage series developed HH following
LSG; one was revised 14 months postsurgery to RYGB,
and the other, who received to a BPD/DS 5 months after the
sleeve, underwent cruroplasty and fundectomy 38 months
after the second stage because of untreatable symptoms. In
this case, in a 50-year-old woman with a preoperative BMI
of 78 kg/m2, HH was not clearly recognized during her
LSG procedure, and a complete fundectomy was difficult to
achieve at that time; thus, during the revisional cruroplasty
(at which time the patient had a BMI of 27 kg/m2), a re-
resection of the fundus was performed to control her reflux
symptoms (Fig. 1). The fundectomy was performed with
the use of reinforced 45-mm blue cartridges close to a 40 Fr
gastric bougie. The assistant surgeon exposed the fundus
using posterolateral traction while the surgeon applied
traction on the sleeved stomach with the left hand, and
transected the stomach with the linear stapler in the right
hand, as close to the 40 Fr gastric bougie as possible.
Weight Loss
In the follow-up of 55 patients at the postoperative 6-month
point, BMI decreased 24.7% to 37.5±9.3 (range 22.2–58.1)
representing a significant change of −12.3 from baseline
(p<0.001). Total group %EWL at 6 months was 48.1±19.3
(15.5–98.9) (Table 3). In the subgroup analysis of %EWL at
6 months, there were no significant differences between
males and females, age groups (<33, ≥33–<43, ≥43 years),
or comorbidity group (comorbidity presence vs. not present);
however, a significant difference was found between BMI
subgroups (<40, ≥40–<50, ≥50; p<0.001). Nonparametric
ANOVA followed by independent Mann–Whitney U tests
Table 2 Concomitant procedures and complications in 121 patients
Concomitant procedure N (%)
Cholecystectomy 8 (6.7)
Omentectomy 1 (0.8)
Biliointestinal bypass restoration 1 (0.8)
Umbilical hernia repair 7 (5.8)
Hiatal hernia reduction and cruroplasty 15 (12.6)
Complication N (%)
Intraoperative leak 1 (0.8)
Stricture 1 (0.8)
Extraluminal bleeding (trocar site) 1 (0.8)
Acute renal failure 1 (0.8)
Wound infection 2 (1.7)
Postoperative leak 0 (0.0)
Fig. 1 Laparoscopic sleeve gastrectomy and hiatal hernia. Pts
patients, BPD/DS biliopancreatic diversion/duodenal switch, RYGB
Roux-en-Y gastric bypass
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revealed significant differences between the lowest and
highest BMI groups, and also between the mid-range BMI
and highest BMI groups, but no statistically significant
difference between the lowest and the mid-range BMI
groups (Table 3). Figure 2 presents mean BMI and %EWL
following LSG with respect to time from 1 to 48 months. At
12 months (n=41), BMI was 38.4±10.5 (19.3–62.3) with
51.7±25.0 (8.9–123.3) %EWL; at 24 months (n=23), BMI
was 37.5±7.5 (24.7–49.7) with 53.1±16.6 (25.3–84.5) %
EWL; at 36 months (n=11), BMI was 35.5±8.8 (25.9–51.9)
with 63.9±14.0 (35.2–81.0) %EWL; and at 48 months (n=
13), BMI was 35.6±6.8 (24.9–47.5) with 61.1±12.2 (43.9–
82.1) %EWL.
Table 4 presents the bivariate analysis results investigat-
ing preoperative clinical variables and their potential value
in predicting suboptimal weight loss at 6 months. Pre-
sleeve BMI was the only significant predictor in the
bivariate analysis; however, patient ASA score and pres-
ence of T2DM trended toward significance and were,
therefore, incorporated into the multivariate model.
Figure 3a depicts the results of bivariate correlation analysis
of %EWL and BMI at 6 months (Pearson r=−0.58; p<
0.001). Preoperative BMI accounted for 33.6% of the
variance in %EWL and, as a lone predictor, was found to
correctly classify >70% of patients who experienced <50%
EWL at 6 months. (At 3 years, preoperative BMI accounted
for 72.3% of the variance in %EWL, n=11.) Figure 3b
presents results of logistic regression analysis in the form of
a probability curve. As BMI remained the only significant
predictor (odds ratio=1.13, 95% CI 1.05–1.21, p<0.001) in
the multivariate model, its beta coefficient and associated
constant were used to develop the equation characterizing
the likelihood of suboptimal weight loss (%EWL <50 at
6 months) as a function of preoperative BMI.
Diabetes Subgroup Analysis
Two weeks following LSG, 100% of preoperative T2DM
patients (n=23, mean preoperative T2DM duration 3.7 years
[range 1–10]) were in remission and off all medical therapy.
Mean glycosylated hemoglobin (HbA1C, %) in the diabetic
subgroup was 6.5±0.8, reduced from a baseline HbA1C of
7.6±1.6 (p<0.01); mean glycemic level (mg/dL) was 90.6±
22.4, reduced from 133.9±29.6 (p<0.01). Three-month
data (Table 5) confirmed and reinforced 2-week results:
100% of patients remained off diabetic medication; HbA1C
Table 3 Total and subgroup weight loss at 6 months
Total group Value N=55
Mean ± SD (range) Mean change (% change) 95% CI p valuea
Absolute weight (kg) 103.0±26.8 (59.6–165.9) −33.9 (24.8) −37.7–−30.2b <0.001
BMI (kg/m2) 37.5±9.3 (22.2–58.1) −12.3 (24.7) −13.6–−11.0b <0.001
EWL (%) 48.1±19.3 (15.5–98.9) – 42.9–53.3c –
Subgroups N Mean ± SD (range) 95% CIc p value
EWL (%), by gender
Females 37 48.1±20.2 (15.5–98.9) 41.4–54.8 NSd
Males 18 48.1±17.8 (17.4–82.6) 39.2–57.0
EWL (%), by age (years)
<33 18 53.3±21.8 (15.5–87.6) 42.5–64.1 NSe
≥33–<43 16 45.2±19.6 (20.8–98.9) 34.8–55.6
≥43 21 45.9±16.7 (17.4–71.6) 38.3–53.5
EWL (%), by BMI
<40 12 63.3±20.5 (29.4–98.9) 50.3–76.3 <0.001e
≥40–<50 15 54.7±11.7 (29.4–70.3) 48.2–61.2
≥50 28 38.0±16.5 (15.5–86.9) 31.6–44.4
EWL (%), by comorbidity
Present 29 46.2±19.9 (15.5–98.9) 38.6–53.8 NSd
Not present 26 50.2±18.7 (20.8–87.6) 42.7–57.8
BMI body mass index, EWL excess weight loss, CI confidence interval
a Paired samples t test assessing change from baseline
b 95% CI of mean difference
c 95% CI of the mean
d Independent samples Mann–Whitney U test
e Kruskal–Wallis one-way ANOVA
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was 5.9±0.5, a decrease of 22.4% from baseline (p<0.001);
and mean glycemic level, 90.0±19.9, a decrease of 32.8%
from baseline (p<0.01). Cholesterol and triglyceride reduc-
tion in the T2DM subgroup trended toward significance. In
addition, at 3 months, diabetic subgroup BMI decreased
18.7% from baseline (p<0.01) with a mean %EWL of
37.2±11.7 (18.8–53.1), which was not significantly differ-
ent from %EWL of the nondiabetic subgroup (34.1±13.0
[16.0–66.5]).
Discussion
San Giovanni Bosco Hospital, Naples, has steadily increased
its annual use of the LSG procedure since 2002; this is
consonant with increased performance of SG in Italy, and
globally [24, 33]. We began performing LSG as the first step
of a two-stage procedure (BPD-DS) in super-obese patients
(1/62 cases in 2002, 4/74 [2003], 6/100 [2004], 3/100
[2005], 3/97 [2006]). Considering the minimal morbidity and
complications experienced by our patients, combined with
satisfactory weight loss, in 2007, we began offering LSG as
a definitive procedure for the treatment of mild obesity as
well, extending this procedure to a larger number of patients
(15/102 [2007], 19/96 [2008], 67/110 [2009], 148/169
[2010]).
In the current study, our early findings of 48.1% and
51.7% EWL at 6 and 12 months, respectively, are in the
range of the mean EWL, 55.4%, reported in the systematic
review of 2,570 SG patients (36 studies, 3–60 month
follow-up) by Brethauer et al. [15], and 60.7% in a large
international questionnaire-based consensus review (repre-
senting 14,776 SG patients, 12-month follow-up) by
Gagner et al. [34]. Other approved bariatric procedures
realize a weight-loss zenith at 2–4 years with some weight
regain at 3–5 years. In the only >5-year SG series with




















0 1 3 6 12 24 36 48
Time (months) 
Fig. 2 Body mass index (BMI) and percentage excess weight loss (%
EWL) with respect to time following laparoscopic sleeve gastrectomy
Table 4 Bivariate analysis of preoperative clinical variables with respect to weight loss following sleeve gastrectomy at 6 months
Variable <50% EWL (N=29) ≥50% EWL (N=26) p value
Age 39.5±10.5 38.1±11.3 NSa
Male sex 9 (31.0%) 9 (34.6%) NSb
BMI 54.2±8.8 45.0±8.2 <0.001a
ASA score 3.6±0.6 3.4±0.7 NSa (0.16)
Number of comorbidities 1.2±1.4 0.9±1.2 NSa
Comorbidity
Hypertension 12 (41.4%) 12 (46.2%) NSb
OSA 9 (31.0%) 6 (23.1%) NSb
T2DM 8 (27.6%) 3 (11.5%) NSb (0.13)
Hyperlipidemia 5 (17.2%) 2 (7.7%) NSb
EWL excess weight loss, BMI body mass index, ASA American Society of Anesthesiologists (physical status classification score), OSA obstructive
sleep apnea, T2DM type 2 diabetes mellitus
Data are expressed as mean ± SD for continuous variables, and N (%) for categorical variables
aMann–Whitney U test
b Fisher's exact test
OBES SURG (2011) 21:783–793 789
complete follow-up (n=26), a 2010 study by Bohdjalian et
al., 3-year EWL was 60%, and 55% at 5 years [35].
Although only a small number of LSG patients in our study
had reached 3-year (63.9% EWL) and 4-year (61.1% EWL)
follow-up, their weight loss suggests a similar trend.
In our series, the lowest BMI group (<40) experienced
the greatest %EWL, significantly more than the highest
BMI group (≥50). When treated as a continuous variable,
correlation and logistic regression analyses demonstrated
that preoperative BMI was predictive of suboptimal weight
loss. This analysis, and resultant probability curve, may be
useful in aiding patients to visualize their likelihood of
requiring a second operation, and may promote realistic
weight-loss expectations. For example, a patient with a pre-
LSG BMI of 48.5 would have a 50% chance of
experiencing a 6-month outcome of <50% EWL, whereas
a pre-LSG BMI of 69 would predict a 90% chance of <50%
EWL at 6 months. This finding may be due to the fact that
the patients with a higher preoperative BMI were initially
subjected to temporary IB treatment which resulted in
substantial weight loss prior to undergoing LSG.
Rapid improvement of T2DM following the primarily
restrictive SG typically occurs within weeks of surgery,
similar to that following primarily malabsorptive proce-
dures. In the current study, mean HbA1C, glycemia, and
triglyceride levels were reduced to within normative
reference ranges at 3 months after surgery, and 100% of
the T2DM subgroup no longer required T2DM medication.
The percentage of those in whom T2DM resolved was
superior to resolution observed in the majority of SG
reports, which ranges from 14% to 100% [5–7, 36–45].
There was no mortality in our series. In two recent
reviews of LSG (n=3,510), mortality ranged from 0.17% to
0.24% [15, 46]. The overall complication rate ranges from
0% to 24% (mean 9.4% high-risk/staged, 6.2% primary
[15]) in the SG literature; complications in the current study
were low, 5.0%. Hiatal hernia, sometimes with gastro-
esophageal reflux disease (GERD), is a frequent occurrence
in the obese (15% incidence symptomatic HH in BMI >35
[47]), and in most instances, bariatric surgery successfully
treats the hernia (restoring cardioesophageal competence
[48, 49]), obesity, and GERD [50]. In our series of 15
patients with HH operated concomitantly with LSG, three
(20%) recurred, one was revised to RYGB, and two await
reoperation. Of patients who developed HH postoperatively
(patients of the two-stage series), one was revised 14 months
postsurgery to RYGB, and the other, who received a BPD/
DS 5 months after the sleeve, underwent cruroplasty and
fundectomy 38 months after the second stage because of
untreatable symptoms.
In the super-super obese patients undergoing LSG, it
may be very difficult to recognize a crural defect, and
especially considering the aim of this “salvage operation,”
it might not be indicated to perform complex and risky
esophageal dissection. In the case of a 50-year-old woman
with a preoperative BMI of 78 kg/m2, during her LSG
procedure, HH was not clearly recognized, and a complete
fundectomy was not attempted at that time. SG can improve
or ameliorate symptoms of preoperative GERD in 40% to
85% of patients if there is successful crural repair [51]. In
the authors' experience, “trans-hiatal sleeve migration” with
crural dehiscence carries severe GERD symptom recur-
rence. When HH cannot be satisfactorily repaired at time of
LSG, conversion to RYGB should be considered. In
r = –0.58 




Fig. 3 a Scatter plot and regression line depicting inverse relationship
between preoperative body mass index (BMI) and percentage excess
weight loss (%EWL) following laparoscopic sleeve gastrectomy at
6 months. b Probability curve characterizing likelihood of patient with
a given preoperative BMI experiencing %EWL <50 6 months
following laparoscopic sleeve gastrectomy. For example, a patient
with a pre-sleeve BMI of 48.5 is predicted to have a 50% chance of
experiencing a 6-month weight-loss outcome of <50% EWL, whereas
a patient with a pre-sleeve BMI of 69 is predicted to have a 90%
chance of experiencing a 6-month weight-loss outcome of <50% EWL
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reference to this problem, Himpens et al. [52], in their long-
term study, had preoperatively excluded patients with
significant GERD and reported 23% to 26% of patients
suffering from frequent episodes of GERD. They also claim
that the “neo-fundus” formation was responsible for both
weight regain and GERD. With these indications, two
patients in their series were re-sleeved. In this classic paper,
no mention is made of crural dissection and repair.
Although incidence of anastomotic leak is relatively low
in SG, 2.2% (0% to 20%) [53], its potential to increase
morbidity, length of hospital stay, and mortality is great,
and there is no agreed standard procedure for leak
prevention. Kasalicky et al. report no leak at 18-month
SG follow-up without a reinforced staple line; their
technique incorporates waiting 30–60 s after stapler closure
before firing, use of 1–2 interrupted stitches to control
bleeding, and covering the staple line with 100% oxygen-
ous cellulose to prevent residual bleeding [42]. However,
the 2009 international summit on SG reported that staple-
line reinforcement was employed by 65.1% of surgeon
responders; 42.1% used buttressing material, 50.9% over-
sewed, and 7.0% used both methods [34]. Surgeons have
employed running or interrupted absorbable or nonabsorb-
able sutures to oversew the transection line, as well as
segments of dehydrated bovine pericardium (Per-Strips
Dry® [PSD], Synovis), absorbable polymer (Seamguard®,
Gore), and fibrin sealants. A randomized trial of buttressing
material used in SG by Dapri et al. found no significant
difference in postoperative leak between no reinforcement,
Seamguard, and suturing (PSD was not a comparator) [54].
Other studies have evaluated PSD efficacy in their
procedures and demonstrated minimization of leak [26,
55–58]. In a prior randomized trial at our institution, RYGB
staple-line reinforcement with PSD mounted on the linear
stapler was shown to significantly reduce extraluminal
bleeding, obtain a dry operating field, abbreviate operating
time, and also, reduce leak [26]. This evidence combined
with that of prior SG studies with good results using PSD
buttressing influenced our use of the same material to
reinforce the transection line in SG. The incidence of leak
in the current study was 0. Although there was no
controlled comparison, we speculate that the use of PSD
reinforcement was a central factor in this outcome. Since
summarizing the current data, we have continued our series
of reinforced LSGs, now totaling 250 patients, 42 with
cruroplasty, maintaining 0 gastric leaks and no mortality.
A limitation of the study is that it was retrospective and
lacked a controlled comparison group. Also, early staged
procedures in high-risk patients were combined with
primary operations, and comorbidity data other than for
T2DM were not studied in detail.
In conclusion, improved strategies for diagnosis and
management of hiatal hernia preoperatively and intraoper-
atively in SG are needed; crural repair pledgets and/or
mesh, and the associated procedure for their implementa-
tion, require standardization. The combination of meticu-
lous surgical technique, PSD reinforcement of the gastric
staple line, and a low threshold of conversion to RYGB or
Table 5 Metabolic outcomes for diabetic patients at 3 months
Outcome Value
Mean ± SD (range) N=23
Preop Postop Mean change (% change) p valuea
Absolute weight (kg) 137.6±31.3 (80.0–196.2) 111.6±26.2 (72.0–149.0) −26.0 (18.9) <0.01
BMI (kg/m2) 50.8±8.9 (34.0–62.4) 41.3±7.9 (32.3–54.9) −9.5 (18.7) <0.01
Systolic BP (mmHg) 123.3±5.8 (110.0–140.0) 120.0±10.0 (110.0–130.0) −3.3 (2.7) NS
Diastolic BP (mmHg) 82.0±2.0 (60.0–90.0) 72.0±10.6 (60.0–80.0) −10.0 (12.2) NS
Glycemia (mg/dL) 133.9±29.6 (93.0–234.0) 90.0±19.9 (62.0–116.0) −43.9 (32.8) <0.01
OGTT (mg/dL) 138.1±46.4 (92.0–232.0) 87.3±20.3 (62.0–122.0) −50.8 (36.8) <0.05
HbA1C (%) 7.6±1.6 (6.2–13.5) 5.9±0.5 (5.3–7.2) −1.7 (22.4) <0.001
Cholesterol (mg/dL) 217.4±47.6 (138.0–289.0) 198.9±35.4 (133.0–297.0) −18.5 (8.5) NS (0.07)
HDL (mg/dL) 46.4±9.8 (29.0–56.0) 43.6±5.7 (36.0–60.0) −2.8 (6.0) NS
LDL (mg/dL) 122.8±35.5 (69.0–184.0) 122.5±33.6 (72.0–172.0) −0.3 (0.2) NS
Triglycerides (mg/dL) 239.6±157.6 (83.0–567.0) 132.6±45.2 (86.0–215.0) −107.0 (45.0) NS (0.09)
Preop preoperative, Postop postoperative, BMI body mass index, BP blood pressure, OGTT oral glucose tolerance test, HbA1C glycosylated
hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein
a Paired samples t test assessing change from baseline
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BPD/DS make SG a safe and effective operation in the
short term. Weight loss and T2DM outcomes for SG require
confirmation over the long term.
Acknowledgments We thank Giuliana Vitolo and Maria Police of
the Department of Surgery, San Giovanni Bosco Hospital, Naples,
Italy, for their invaluable help in collecting the data, and for their
support in the management and follow-up of patients. This work was
supported by Synovis Life Technologies, Inc.
Conflict of Interest The authors declare that they have no conflict
of interest.
References
1. Clinical Issues Committee of the American Society for Metabolic
and Bariatric Surgery. Updated position statement on sleeve
gastrectomy as a bariatric procedure. Surg Obes Relat Dis.
2010;6(1):1–5.
2. North American Association for the Study of Obesity (NAASO)
and the National Heart, Lung, and Blood Institute (NHLBI). The
Practical Guide: identification, evaluation, and treatment of
overweight and obesity in adults. NIH Publication #00-4084,
October 2000.
3. Regan JP, Inabnet WB, Gagner M, et al. Early experience with
two-stage laparoscopic Roux-en-Y gastric bypass as an alternative
in the super-super obese patient. Obes Surg. 2003;13:861–4.
4. Almogy G, Crookes PF, Anthone GJ. Longitudinal gastrectomy as
a treatment for the high-risk super-obese patient. Obes Surg.
2004;14:492–7.
5. Hamoui N, Anthone GJ, Kaufman HS, et al. Sleeve gastrectomy
in the high-risk patient. Obes Surg. 2006;16:1445–9.
6. Silecchia G, Boru C, Pecchia A, et al. Effectiveness of
laparoscopic sleeve gastrectomy (first stage of biliopancreatic
diversion with duodenal switch) on co-morbidities in super-obese
high-risk patients. Obes Surg. 2006;16:1138–44.
7. Cottam D, Qureshi FG, Mattar SG, et al. Laparoscopic sleeve
gastrectomy as an initial weight-loss procedure for high-risk
patients with morbid obesity. Surg Endosc. 2006;20:859–63.
8. Lee CM, Cirangle PT, Jossart GH. Vertical gastrectomy for
morbid obesity in 216 patients: report of two-year results. Surg
Endosc. 2007;21:1810–6.
9. Nocca D, Krawczykowsky D, Bomans B, et al. A prospective
multicenter study of 163 sleeve gastrectomies: results at 1 and
2 years. Obes Surg. 2008;18:560–5.
10. Tucker ON, Szomstein S, Rosenthal RJ. Indications for sleeve
gastrectomy as a primary procedure for weight loss in the
morbidly obese. J Gastrointest Surg. 2008;12:662–7.
11. Felberbauer FX, Langer F, Shakeri-Manesch S, et al. Laparoscopic
sleeve gastrectomy as an isolated bariatric procedure: intermediate
term results from a large series in three Austrian centers. Obes
Surg. 2008;18:814–8.
12. Skrekas G, Lapatsanis D, Stafyla V, et al. One year after
laparoscopic “tight” sleeve gastrectomy: technique and outcome.
Obes Surg. 2008;18:810–3.
13. Langer FB, Bohdjalian A, Shakeri-Leidenmühler S, et al. Conversion
from sleeve gastrectomy to Roux-en-Y gastric bypass—indications
and outcome. Obes Surg. 2010;20(7):835–40.
14. Uglioni B, Wölnerhanssen B, Peters T, et al. Midterm results of
primary vs. secondary laparoscopic sleeve gastrectomy (LSG) as
an isolated operation. Obes Surg. 2009;19(4):401–6. Epub 2009
Jan 24.
15. Brethauer SA, Hammel JP, Schauer PR. Systematic review of
sleeve gastrectomy as staging and primary bariatric procedure.
Surg Obes Relat Dis. 2009;5:469–75.
16. Sánchez-Santos R, Masdevall C, Baltasar, et al. Short- and mid-
term outcomes of sleeve gastrectomy for morbid obesity: the
experience of the Spanish National Registry. Obes Surg. 2009;19
(9):1203–10.
17. Rubin M, Yehoshua RT, Stein M, et al. Laparoscopic sleeve
gastrectomy with minimal morbidity: early results in 120
morbidly obese patients. Obes Surg. 2008;4:33–8.
18. Serra C, Pérez N, Bou R, et al. Laparoscopic sleeve gastrectomy.
A bariatric procedure with multiple indications. Cir Esp. 2006;79
(5):289–92.
19. Abu-Jaish W, Rosenthal RJ. Sleeve gastrectomy: a new surgical
approach for morbid obesity. Expert Rev Gastroenterol Hepatol.
2010;4(1):101–19. Review.
20. Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss,
appetite suppression, and changes in fasting and postprandial
ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and
sleeve gastrectomy: a prospective, double blind study. Ann Surg.
2008;247(3):401–7.
21. Himpens J, Dapri G, Cadière GB. A prospective randomized
study between laparoscopic gastric banding and laparoscopic
isolated sleeve gastrectomy: results after 1 and 3 years. Obes Surg.
2006;16(11):1450–6.
22. Omana JJ, Nguyen SQ, Herron D, et al. Comparison of comorbidity
resolution and improvement between laparoscopic sleeve gastrecto-
my and laparoscopic adjustable gastric banding. Surg Endosc.
2010;24(10):2513–7.
23. Akkary E, Duffy A, Bell R. Deciphering the sleeve: technique,
indications, efficacy, and safety of sleeve gastrectomy. Obes Surg.
2008;18(10):1323–9. Epub 2008 Jun 6.
24. Buchwald H, Oien D. Metabolic/bariatric surgery worldwide
2008. Obes Surg. 2009;19(12):1605–11.
25. Moy J, Pomp A, Dakin G, et al. Laparoscopic sleeve gastrectomy
for morbid obesity. Am J Surg. 2008;196(5):e56–9.
26. Angrisani L, Lorenzo M, Borrelli V, et al. The use of bovine
pericardial strips on linear stapler to reduce extraluminal bleeding
during laparoscopic gastric bypass: prospective randomized
clinical trial. Obes Surg. 2004;14(9):1198–202.
27. World Medical Association (WMA) Declaration of Helsinki—
ethical principles for medical research involving human subjects.
Adopted by the 18th WMA General Assembly, Helsinki, Finland,
June 1964, amended by the 59th WMA General Assembly, Seoul,
October 2008. World Med J 2008;54(4):122–5.
28. Sauerland S, Angrisani L, Belachew M, et al. Obesity surgery:
evidence-based guidelines of the European Association for
Endoscopic Surgery (EAES). Surg Endosc. 2005;19(2):200–21.
29. Fried M, Hainer V, Basdevant A, et al. Inter-disciplinary European
guidelines on surgery of severe obesity. Int J Obes. 2007;31:569–77.
30. Clinical Guidelines on the Identification, Evaluation, and Treatment
of Overweight and Obesity in Adults; The Evidence Report.
Bethesda, MD; September 1998. NIH Publication: National Institute
of Health, National Heart, Lung and Blood Institute (NHLBA) in
cooperation with The National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDKD).
31. Metropolitan height and weight tables. Stat Bull Metropol Life
Found 1983;64:3–9.
32. Miller RD, editor. Miller’s anesthesia. Philadelphia: Elsevier
Churchill Livingstone; 2005.
33. Societa Italiana di Chirurgia dell’Obesita. Bariatric Surgery
Survey, 2008.
34. Gagner M, Deitel M, Kalberer TL, et al. The Second International
Consensus Summit for Sleeve Gastrectomy, March 19–21, 2009.
Surg Obes Relat Dis. 2009;5(4):476–85. Epub 2009 Jun 13.
792 OBES SURG (2011) 21:783–793
35. Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, et al. Sleeve
gastrectomy as sole and definitive bariatric procedure: 5-year
results for weight loss and ghrelin. Obes Surg. 2010;20(5):535–
40. Epub 2010 Jan 22.
36. Abbatini F, Rizzello M, Casella G, et al. Long-term effects of
laparoscopic sleeve gastrectomy, gastric bypass, and adjustable
gastric banding on type 2 diabetes. Surg Endosc. 2010;24
(5):1005–10. Epub 2009 Oct 29.
37. Rizzello M, Abbatini F, Casella G, et al. Early postoperative
insulin-resistance changes after sleeve gastrectomy. Obes Surg.
2010;20(1):50–5. Epub 2009 Nov 15.
38. Weiner RA, Weiner S, Pomhoff I, et al. Laparoscopic sleeve
gastrectomy—influence of sleeve size and resected gastric
volume. Obes Surg. 2007;17:1297–305.
39. Moon Han S, Kim WW, Oh JH. Results of laparoscopic sleeve
gastrectomy (LSG) at 1 year in morbidly obese Korean patients.
Obes Surg. 2005;15:1469–75.
40. Gan SS, Talbot ML, Jorgensen JO. Efficacy of surgery in the
management of obesity-related type 2 diabetes mellitus. ANZ J
Surg. 2007;77:958–62.
41. Ou Yang O, Loi K, Liew V, et al. Staged laparoscopic sleeve
gastrectomy followed by Roux-en-Y gastric bypass for morbidly
obese patients: a risk reduction strategy. Obes Surg.
2008;18:1575–80.
42. Kasalicky M, Michalsky D, Housova J, et al. Laparoscopic sleeve
gastrectomy without an over-sewing of the staple line. Obes Surg.
2008;18:1257–62.
43. Vidal J, Ibarzabal A, Romero F, et al. Type 2 diabetes mellitus and
the metabolic syndrome following sleeve gastrectomy in severely
obese subjects. Obes Surg. 2008;18:1077–82.
44. Tagaya N, Kasama K, Kikkawa R, et al. Experience with
laparoscopic sleeve gastrectomy for morbid versus super morbid
obesity. Obes Surg. 2009;19:1371–6.
45. Gill RS, Birch DW, Shi X, et al. Sleeve gastrectomy and type 2
diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6
(6):707–13.
46. Shi X, Karmali S, Sharma AM, et al. A review of laparoscopic
sleeve gastrectomy for morbid obesity. Obes Surg. 2010;20:1171–7.
47. Ovrebo KK, Hatlebakk JG, Viste A, et al. Gastroesophageal reflux
in morbidly obese patients treated with gastric banding or vertical
banded gastroplasty. Ann Surg. 1998;228:51–8.
48. Dolan K, Finch R, Fielding G. Laparoscopic gastric banding and
crural repair in the obese patient with a hiatal hernia. Obes Surg.
2003;13:772–5.
49. Frezza EE, Ikramuddin S, Gourash TR, et al. Symptomatic
improvement in gastroesophageal reflux disease (GERD) following
laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2002;16:1027–
31.
50. Angrisani L, Iovino P, LorenzoM, et al. Treatment of morbid obesity
and gastroesophageal reflux with hiatal hernia by Lap-Band. Obes
Surg. 1999;9(4):396–8.
51. Soricelli E, Casella G, Rizzello M, et al. Initial Experience with
laparoscopic crural closure in the management of hiatal hernia in
obese patients undergoing sleeve gastrectomy. Obes Surg.
2010;20:232–5.
52. Márquez MF, Ayza MF, Lozano RB, et al. Gastric leak after
laparoscopic sleeve gastrectomy. Obes Surg. 2010;20:1306–11.
53. Dapri G, Cadière GB, Himpens J. Reinforcing the staple line
during laparoscopic sleeve gastrectomy: prospective randomized
clinical study comparing three different techniques. Obes Surg.
2010;20(4):462–7. Epub 2009 Dec 11.
54. Stammberger U, Klepetko W, Stamatis G, et al. Buttressing the
staple line in lung volume reduction surgery: a randomized three-
center study. Ann Thorac Surg. 2000;70(6):1820–5.
55. Himpens J, Dobbeleir J, Peeters G. Long-term results of laparoscopic
sleeve gastrectomy for obesity. Ann Surg. 2010;252:319–24.
56. Shikora SA. The use of staple-line reinforcement during laparoscopic
gastric bypass. Obes Surg. 2004;14(10):1313–20. Review.
57. Shikora SA, Kim JJ, Tarnoff ME. Comparison of permanent and
nonpermanent staple line buttressing materials for linear gastric
staple lines during laparoscopic Roux-en-Y gastric bypass. Surg
Obes Relat Dis. 2008;4(6):729–34. Epub 2008 Jun 30.
58. Daskalakis M, Berdan Y, Theodoridou S, et al. Impact of surgeon
experience and buttress material on postoperative complications
after laparoscopic sleeve gastrectomy. Surg Endosc. 2011;25(1):88–
97.
OBES SURG (2011) 21:783–793 793
